1. How has Merck been able to achieve substantial returns to capital given the large costs and lengthy time to develop drugs? Merck had a 14% increase in sales between 1997 and 1998 and 22% increase in sales from 1998 – 1999‚ and a 13% annual increase in earnings over the same period. Merck’s business strategy consists of two parts: (1) developing and marketing new drugs through internal research‚ and (2) developing partnerships with smaller biotechnology companies. Since 1995‚ Merck had launched
Premium Expected value License Money
Pharmaceuticals: Merck Sustaining Long-term Advantage Through Information Technology Hiroshi Amari Working Paper No. 161 Working Paper Series Center on Japanese Economy and Business Columbia Business School December 1998 Columbia-Yale Project: Use of Software to Achieve Competitive Advantage PHARMACEUTICALS: MERCK Sustaining Long-term Advantage Through Information Technology Prepared by Hiroshi Amari Research Associate‚ Yale University William V. Rapp and Hugh T. Patrick Co-principal
Premium Clinical trial Pharmaceutical industry Drug development
Merck & Co.‚ Inc (A) (The summary is based on the article in Vol. I and does not include the extra readings given by the professor) This case is a classic example of enterprises trying to balance their business of increasing profits and expected social responsibilities. This dilemma is further accentuated when the company happens to be a pharma company whose decisions directly affect people’s lives. The Dilemma: A possible drug for River Blindness‚ a disease which affects almost 85 million
Premium Pharmacology Medicine Affect
Case #1: Merck and River Blindness MGT 597: Leadership Ethics Dr. Brandon Randolph-Seng Javiaur Harmon: Winter Mini 2014 - 2015 1. Think about the definition stakeholders—any parties with a stake in the organization’s actions or performance. Who are the stakeholders in this situation? How many can you list? On what basis would you rank them in importance? The stakeholders in this situation were the employees (research scientists doing the R&D)‚ Merck‚ and the target audience which
Premium Value system Risk Intrinsic value
Questions for the Merck Case Create a decision tree for Merck. The 2 leftmost branches would identify the alternatives related to licensing Davarink (specifically license versus not to license). Next‚ if Merck decides to pursue license‚ they go into phase I which results in a success‚ or failure. Phase I success is followed by phase II where Merck has the opportunity to develop the drug to treat depression alone‚ weight loss alone‚ or both‚ or contemplate phase II failure. Finally phase
Premium Decision tree Decision theory
Executive Summary Merck & Company has been presented with an opportunity to invest $30 million for the purchasing rights of an obesity and high cholesterol lowering drug‚ KL-798 from Kappa Labs. Based on the expected probabilities of success through each product-development phase for this new drug‚ as well as the costs involved‚ the net present value of the project is -$1.16 million and is therefore recommended that Merck passes on the investment. Sensitivity analysis also show that adjusting
Premium Clinical trial Net present value Investment
Running head: CASE STUDY: MERCK & COMPANY: THE VIOXX RECALL Merck & Company: The Vioxx Recall Albert Balogun California Baptist University BUS 520A: Managerial Ethics Jim Bishop‚ PhD June 30‚ 2010 Merck & Company: The Vioxx Recall The issues involved in Merck‚ a pharmaceutical manufacturing company’s recall of one its products‚ Vioxx‚ is the effect of direct-to-consumer (DTC) advertising of prescription drug on the society public
Premium Pharmacology Food and Drug Administration Pharmaceutical industry
Merck & Co.‚ Inc. Case If one hold a key to resolve a very serious problem‚ one has a responsibility to put an effort to make it happen‚ at least try one’s best. In this case‚ river blindness disease was a very serious problem‚ and Dr. Vagelos was the one who could make a decision as to whether the research and development of a human version of ivermectin should be carried on‚ then it was his responsibility to pursue it. Caused by a parasitic worm carried by a tiny black fly‚ the disease
Premium Blindness Human Onchocerciasis
Merck Ethics Study In developing a drug to combat river blindness‚ pharmaceutical company Merck discovered an opportunity to treat millions of affected peoples around the world that probably would never see commercial use. The drug in development‚ ivermectin‚ was unaffordable to the primary victims of river blindness‚ Third World peoples. Thus‚ Dr. Vagelos‚ the head of research at the time‚ treaded upon a ethical quagmire; he could either choose to scrap the drug and its further research or
Premium Ethics Philosophy of life Person
Furthermore‚ change blindness has been detected in many other studies. In most cases‚ observers do not notice changes that are introduced‚ particularly when these changes occur during disruptions such a blank screen‚ a blink or an eye movement (Simons). Change blindness occurs whenever attention is diverted from the change signal. Additionally‚ changes to objects that are significant to the meaning of the scene or changes to visually distinctive objects are detected more rapidly than other changes
Premium